Stage IV Melanoma Patients With Unresectable Liver Metastases
Conditions
Brief summary
The Aim is to evaluate safety and efficacy of TACE with doxorubicin-loaded DC beads in melanoma patients with liver metastasis. This is a pilot study with the aim of recruiting 20 patients, this is a feasibility study. the patients profile is patients with stage IV Melanoma with liver metastases.
Interventions
DEVICETACE using Drug Eluting Beads loaded with Doxorubicin
100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
Sponsors
University Hospital Tuebingen
SLK Kliniken Heilbronn GmbH
Heidelberg University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with unresectable, measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST and EASL criteria (2D/3D-EASL) or MRI (Extent of Necrosis) 2. Patients ≥ 18 years of age, \> 35kg, of any race or sex, who have histological or radiological proof of melanoma to the liver 3. ECOG performance status \< 3. 4. Patient chooses to participate and has signed the informed consent document. 5. Patients with unilobar disease who can be treated superselectively in a single session or patients with bilobar disease who can have both lobes able to be treated within 3 - 4 weeks in separate sessions. 6. Patients with patent main portal vein. 7. Ocular melanoma is allowed. 8. Patients with clinically and radiologically stable brain metastasis from melanoma can be included. 9. Patients with liver dominant disease (\>50% overall tumor burden). 10. Prior systemic therapy for metastatic disease is allowed. 11. Non-pregnant with an acceptable contraception in premenopausal women and fertile men. 12. Hematological function: ANC ≥1.5 x 109/L, platelets ≥ 75 x 109/L, INR\<1.3 (patients on therapeutic anticoagulants are not eligible). 13. Adequate renal function: Creatinine ≤2.0mg/dl and GFR \>30. 14. Adequate liver function: total bilirubin ≤ 2.5 mg/dl, ALT, AST ≤ 5 times ULN, albumin ≥ 2.5mg/dl. 15. All toxic effects of prior therapy must have resolved to ≤ Grade 1 unless otherwise specified above
Exclusion criteria
1. Women who are pregnant or breast feeding. 2. Patients eligible for curative treatment such as resection or radiofrequency ablation. 3. Active bacterial, viral or fungal infection within 72 hours of study entry. 4. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated \< 5 years prior to study entry. 5. Contraindication to hepatic artery embolization procedures: \- Severe peripheral vascular disease precluding catheterization. 6. \- Large shunt as determined by the investigator (pretesting with TcMAA not required) at the time of first angiogram. 7. -Hepatofugal blood flow. 8. -Main portal vein occlusion (e.g. thrombus or tumor). 9. Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment. 10. Allergy to contrast media that cannot be managed with standard care (e.g. steroids), making magnetic resonance imaging (MRI) or computed tomography (CT) contraindicated. 11. Advanced liver disease (\> 80% liver replacement). 12. Other significant medical or surgical condition, or any medication or treatment that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation. 13. Ongoing systemic cancer treatment. 14. Any contraindication for Doxorubicin administration: 15. WBC \<3000 cells/mm3 16. Neutrophils \<1500 cells/mm3 17. Deficient cardiac function defined as a LVEF of \<50% normal 18. Allergy to Doxorubicin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients completing scheduled treatment plan | 12 months | Safety: Adverse Events Efficacy: Response to Treatment |
Countries
Germany
Contacts
Primary ContactPhilippe Pereira, MD
Outcome results
None listed